The propofol prodrug GPI 15715 [Aquavan] has achieved its phase-III primary efficacy endpoint

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1482, 2005-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The orexin-OX1/OX2 receptor antagonist ACT 078573 has met its proof-of-concept primary endpoint in primary insomnia.

By  

Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

A Randomized, Placebo-Controlled, Double-Blind Phase III Trial Investigating the Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines Using a Stringent Composite Endpoint

By William Hanke C.   Narins Rhoda S.   Brandt Fredric   Cohen Joel L.   Donofrio Lisa M.   Downie Jeanine   Heinz Moritz   Harrington Laura   McDaniel David H.   Nestor Mark   Schlessinger Joel   Schlöbe Andrea   Taub Amy   Weiss Robert A.  

Dermatologic Surgery, Vol. 39, Iss. 6, 2013-06 ,pp. : 891-899

Elsevier

Access to resources Recommend Favorite

Alexza Pharmaceuticals has announced that it has completed enrolment in its second phase III trial with loxapine

By  

Inpharma, Vol. 1, Iss. 1661, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Millennium Pharmaceuticals has stopped further accrual into its phase II clinical trial investigating the efficacy of bortezomib

By  

Inpharma, Vol. 1, Iss. 1420, 2004-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline (GSK) has discontinued enrolment into its phase III trial of the HIV entry inhibitor, aplaviroc [GW 873140]

By  

Reactions Weekly, Vol. 1, Iss. 1076, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite